BIONDVAX PHARMA/S (BVXV) vs. Fate Therapeutics (FATE) Head-To-Head Survey

Share on StockTwits

BIONDVAX PHARMA/S (NASDAQ:BVXV) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

6.8% of BIONDVAX PHARMA/S shares are owned by institutional investors. Comparatively, 91.8% of Fate Therapeutics shares are owned by institutional investors. 6.0% of BIONDVAX PHARMA/S shares are owned by insiders. Comparatively, 9.9% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares BIONDVAX PHARMA/S and Fate Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIONDVAX PHARMA/S N/A -168.28% -74.56%
Fate Therapeutics -1,405.06% -59.04% -43.70%

Analyst Recommendations

This is a summary of current recommendations and price targets for BIONDVAX PHARMA/S and Fate Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIONDVAX PHARMA/S 0 0 0 0 N/A
Fate Therapeutics 0 1 5 0 2.83

Fate Therapeutics has a consensus price target of $19.50, suggesting a potential upside of 20.82%. Given Fate Therapeutics’ higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than BIONDVAX PHARMA/S.

Valuation and Earnings

This table compares BIONDVAX PHARMA/S and Fate Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BIONDVAX PHARMA/S N/A N/A -$9.96 million ($1.98) -2.73
Fate Therapeutics $4.74 million 221.33 -$66.60 million ($1.19) -13.56

BIONDVAX PHARMA/S has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than BIONDVAX PHARMA/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BIONDVAX PHARMA/S has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Summary

Fate Therapeutics beats BIONDVAX PHARMA/S on 9 of the 12 factors compared between the two stocks.

BIONDVAX PHARMA/S Company Profile

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Gulden  Price Down 7.7% Over Last Week
Gulden Price Down 7.7% Over Last Week
PTON Price Tops $0.0009 on Top Exchanges
PTON Price Tops $0.0009 on Top Exchanges
Vivid Coin Market Capitalization Tops $108,559.00
Vivid Coin Market Capitalization Tops $108,559.00
Etheera  Trading 24% Higher  Over Last Week
Etheera Trading 24% Higher Over Last Week
Analysts Anticipate Consol Energy Inc  Will Announce Quarterly Sales of $379.90 Million
Analysts Anticipate Consol Energy Inc Will Announce Quarterly Sales of $379.90 Million
$168.33 Million in Sales Expected for Kadant Inc.  This Quarter
$168.33 Million in Sales Expected for Kadant Inc. This Quarter


 
© 2006-2019 Zolmax.